Page 1,747«..1020..1,7461,7471,7481,749..1,7601,770..»

The ‘It’ Clown Could Be a Painkiller For Kids, Study Suggests – Inverse

Posted: Published on May 25th, 2017

The upcoming release of the It remake this September spells doom for the rapidly declining reputation of clowns. History has never been totally kind to these powder-faced jokers, but their public image took a hit in 2016 after Jared Leto appeared in Suicide Squad, which may or may not have led to a rash of clown-faced trolls getting arrested across the United States. Will clowns be pegged as weird bad guys forever? Not if a team of Israeli childrens doctors have their say. It turns out that clowns have an unexpectedly analgesic effect on physical pain, at least in kids receiving treatment for cerebral palsy, as their recent study in PLoS One showed. In the paper, published in April, the researchers showed that clown-care can help numb the pain caused by injections, which are used frequently in cerebral palsy treatment. Most children receiving clown-care reported lower pain levels similar to other clown studies, which is the goal of behavioral and cognitive interventions, the researchers wrote, noting that kids that didnt get clown care experienced a high level of pain that was unexpectedly high. The 45 kids with cerebral palsy made an ideal study group because their treatment exposes them to … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on The ‘It’ Clown Could Be a Painkiller For Kids, Study Suggests – Inverse

The Orthopaedic Institute for Children Expands Its Cerebral Palsy Program to Downtown L.A. in Partnership With UCLA … – Digital Journal

Posted: Published on May 25th, 2017

LOS ANGELES--(Business Wire)--The Orthopaedic Institute for Children announced today the expansion of the UCLA/OIC Center for Cerebral Palsy to the institutes downtown Los Angeles campus. The current center is housed at UCLA in West Los Angeles. Concurrent with this expansion OIC also announced the appointment of Rachel Thompson, M.D., as the centers new associate director. Cerebral palsy is the most common childhood disability in the United States, affecting more than 760,000 children and adults nationally. The UCLA/OIC Center for Cerebral Palsy is the only interdisciplinary clinic in Southern California that evaluates and treats people with cerebral palsy throughout the lifespan. The center includes a comprehensive outpatient clinic and the Kameron Gait and Motion Analysis Laboratory (providing an in-depth understanding of a patients movement patterns). Under the leadership of Co-Founder and Director William Oppenheim, M.D., the center is also heavily involved in research in the field of cerebral palsy and in educating both consumers and professionals as to the most up-to-date assessment and treatment approaches for people with cerebral palsy. Dr. Thompson comes to OIC from A.I. DuPont Hospital for Children at the University of Delaware where she completed a fellowship in neuromuscular orthopaedics. She completed her first fellowship in pediatric … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on The Orthopaedic Institute for Children Expands Its Cerebral Palsy Program to Downtown L.A. in Partnership With UCLA … – Digital Journal

A giant leap to independence, one step at a time – The Hindu

Posted: Published on May 25th, 2017

The Hindu A giant leap to independence, one step at a time The Hindu Vipul Shah, a businessman from Ghatkopar whose son Rohan (16) is going through the Vasa treatment for cerebral palsy, says his son had a motor control disorder from birth. He was advised physiotherapy, prescribed huge dosages of drugs, given stem cell ... View post: A giant leap to independence, one step at a time - The Hindu … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on A giant leap to independence, one step at a time – The Hindu

Cystic Fibrosis Drugs, Cancer Treatments: Families Fear Fallout From Health Care Changes – NBC 7 San Diego

Posted: Published on May 25th, 2017

Peter Hodges two daughters fight cystic fibrosis daily, their medications, doctor visits and hospitalizations costing about $1 million in health care benefits a year. Should the Republican-controlled Senate upend insurance similarly to what the House of Representatives has already approved, their lives could be jeopardized, he said. Hodge worries that his older daughter could end up on a newly defined Medicaid, with spending and other limits determined by the states. His younger daughter could face lifetime caps on the amount his insurance plan would pay for her treatment. "People with cystic fibrosis and their families are terrified, absolutely terrified," said Hodge, who works in technology in South Florida. Trump Administration Bolstered by High Employment Rate Congressional attempts to revamp the health care system have been overshadowed by the drama centered on the White House: the Russian meddling in the U.S. presidential election, President Donald Trump's firing of FBI Director James Comey and the appointment of a former FBI director, Robert Mueller, as a special counsel. But even as some political analysts sayTrump'sproblems threaten the GOP legislative agenda, senators have begun discussing health care. And as they do, people across the country are trying to make sense of what Republican efforts … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Cystic Fibrosis Drugs, Cancer Treatments: Families Fear Fallout From Health Care Changes – NBC 7 San Diego

What Phineas Gage’s Injury Taught Us About Frontal Lobes – Lexology (registration)

Posted: Published on May 25th, 2017

In 1848, Phineas Gage, a 25 year old railroad worker, unwittingly became a benchmark of modern neuroscience. Gage was using a tamping iron to pack explosives when a spark ignited the explosive charge, propelling the iron rod through his cheek, behind his eye socket, then upwards through his brain, finally exiting the top of his skull, and landing some distance away. Gage survived, despite the fact that the tamping iron had destroyed much of his left frontal lobe. While it is reported that Gage never lost consciousness following the accident, his once even-tempered personality changed dramatically thereafter, as noted by John Martyn Harlow, the physician who treated him. Gages case became a text book example of how an injury to the brain can produce a change in personality. However, it was also reported that the personality change was temporary and that Gage was able to resume working and normal activity until his death in 1860, 12 years post-injury, as a result of a seizure. Gages case (as well as his skull which was donated to Dr. Harlow by his family) has been studied ever since his death. Most recently, in 2012, researchers combined CT scans of Gages skull with MRI … Continue reading

Posted in Brain Injury Treatment | Comments Off on What Phineas Gage’s Injury Taught Us About Frontal Lobes – Lexology (registration)

Hormones and periodontal disease in menopausal women – MultiBriefs Exclusive (blog)

Posted: Published on May 25th, 2017

Hot flashes, mood changes and fatigue are just a few of the many symptoms commonly associated with menopause. Physicians can recognize its telltale signs based on a patient's medical history and age. When symptoms interfere with the enjoyment of everyday life, doctors can prescribe hormone replacement therapy to help women adjust to these sudden changes. This therapy is more commonly prescribed today than in the past, as doctors see its additional benefit to prevent osteoporosis and other significant medical problems. According to the Cleveland Clinic Journal of Medicine, estrogen deficiency may be to blame for the development of periodontal disease in menopausal or post-menopausal women. Physicians often see osteoporosis and bone loss in women around this age, which can also include the alveolar bone. Loss of bone mineral density in the alveolar bone is also related to periodontal ligament loss, which causes tooth loss with age. Dentists usually become aware of a hormone problem when periodontal disease presents in those who have no previous history of the disease. Dentists who notice a marked difference in bone density in and around the teeth in older females should inquire about the patient's last menstrual cycle. Furthermore, dental professionals need to ask about … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Hormones and periodontal disease in menopausal women – MultiBriefs Exclusive (blog)

Research Report and Overview on Hormone Replacement Therapy Market, 2017-2027 – MilTech

Posted: Published on May 25th, 2017

Hormone Replacement Therapy is any form of hormone therapy where in the patient, in course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones, or to substitute other hormones for naturally occurring hormones. Menopause, is the time in most womens lives when menstrual periods stop permanently, and the woman is no longer able to have children. Menopause typically occurs between 45 and 55 years of age. Medical professionals defined by a decrease in hormone production by the ovaries. In those who have had surgery to remove the uterus but still have ovaries, menopause generally occurs at the time of the surgery or when hormone levels fall. Following the removal of the uterus, symptoms typically occur earlier at the average of 45 years of age. Estrogen and progesterone are female hormones that play important roles in a womans body. Falling levels cause a range of physical and emotional symptoms, including hot flushes, mood swings and vaginal dryness. The aim of hormone replacement therapy is to restore female hormone levels, allowing the body to function normally again. Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3871 Hormone Replacement TherapyMarket: Drivers and Restraints The prime drivers of hormone replacement therapy are increased demand … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Research Report and Overview on Hormone Replacement Therapy Market, 2017-2027 – MilTech

The Handoff: Your Week in Cardiology News – 5/26/17 – The Cardiology Advisor (registration)

Posted: Published on May 25th, 2017

The Handoff: Your Week in Cardiology News - 5/26/17 The Cardiology Advisor (registration) The Handoff is a weekly roundup of cardiology news covering various developments in subspecialties, as well as pharmaceutical industry, association, and society news. Dark chocolate has been linked with many health benefits, and now, there's another to ... and more » See the article here: The Handoff: Your Week in Cardiology News - 5/26/17 - The Cardiology Advisor (registration) … Continue reading

Posted in Cardiology | Comments Off on The Handoff: Your Week in Cardiology News – 5/26/17 – The Cardiology Advisor (registration)

Puma Biotechnology FDA Live Blog – Forbes

Posted: Published on May 25th, 2017

Forbes Puma Biotechnology FDA Live Blog Forbes This is a live blog of the meeting of the Food and Drug Administration's meeting regarding neratinib, a breast cancer drug being developed by Puma Biotechnology. The basic questions to be addressed, per my story from Monday. Puma's not applying to sell ... Why Puma Biotechnology Inc Jumped Higher TodayMotley Fool Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in SessionZacks.com Drilling Down Into Puma Biotechnology, Inc. (PBYI)StockNewsJournal Business Wire (press release) -Seeking Alpha -Smarter Analyst -Zacks all 124 news articles » See the original post here: Puma Biotechnology FDA Live Blog - Forbes … Continue reading

Posted in Biotechnology | Comments Off on Puma Biotechnology FDA Live Blog – Forbes

Amicus Therapeutics: A Rare Find In Biotechnology – Seeking Alpha

Posted: Published on May 25th, 2017

Amicus Therapeutics (NASDAQ:FOLD) is a global biotherapeutics company focused on rare genetic devastating diseases. The company has advanced its precision medicine, Galafold (migalastat), in treating patients in Europe with Fabry disease (alpha galactosidase A deficiency), a rare X-linked genetic lysosomal disorder in which sphingolipids are not metabolized properly. Galafold, an orally administered drug, is the first medicine approved (EMA but not yet FDA) for treatment of Fabry disease. Other goals for 2017 include submitting a J-NDA (Japan) for migalastat, establishing a clinical plan for ATB200/AT2221 in Pompe disease, completion of phase 3 clinical trial in epidermolysis bullosa. FOLD announced its regulatory plan with FDA for U.S. treatment with Galafold in advancing it's Fabry disease program including two phase 3 trials in late 2016. As previously mentioned, the EMA approved use of Galafold for treatment of Fabry disease. The company published data from its pivotal trial in the New England Journal of Medicine. A statistically significant benefit was conferred by Galafold in 50 patients with treatable mutant galactosidase alleles. However, a closer look at the trial endpoints reveals that the study failed to reach its primary endpoints including greater than 50% reduction in GL-3 inclusions per kidney, and if all 67 … Continue reading

Posted in Biotechnology | Comments Off on Amicus Therapeutics: A Rare Find In Biotechnology – Seeking Alpha

Page 1,747«..1020..1,7461,7471,7481,749..1,7601,770..»